What is the 13F Pro Quality Score for NRIX?

13F Pro ranks Nurix Therapeutics, Inc. (NRIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NRIX's current score at https://13fpro.ai/research/NRIX (free sign-up required for the full ranking).

Which hedge funds own the most NRIX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NRIX include BlackRock,, Redmile Group,, Vestal Point Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NRIX as soon as new 13F filings post.

Where does 13F Pro source NRIX data?

All Nurix Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Nurix Therapeutics, Inc. files with the SEC under CIK 1549595. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NRIX in?

Nurix Therapeutics, Inc. (NRIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NRIX research updated on 13F Pro?

NRIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Nurix Therapeutics, Inc.(NRIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1549595 NRIX stock profile & AI dashboard →

13F Pro Quality Score

13.2/100

Rank #2,773 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.4/100

Profitability

2.6/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

2.6/100

Institutional Flow

78.4/100

Revenue Scale

8.6/100

Dilution Risk

5.1/100

NRIX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Nurix Therapeutics, Inc. (NRIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRIX at 13.2/100 on a 32-signal composite quality model, placing it at rank #2,773 of 2,879 stocks — the bottom half of the AI-ranked universe. NRIX scores in the top quartile across institutional flow (78.4). Areas of concern include profitability (2.6) and free cash flow (2.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Nurix Therapeutics, Inc. reports quarterly revenue of $9.0M, net income of $-89.5M, free cash flow of $-98.5M. Top institutional holders of NRIX by reported 13-F value include BlackRock,, Redmile Group,, Vestal Point Capital,, based on the most recent SEC filings. NRIX trades on the Nasdaq exchange and files with the SEC under CIK 1549595. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nurix Therapeutics, Inc. directly from SEC EDGAR. Nurix Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 48 since 2021, currently 13.2 — a declining long-term trajectory across 57 quarterly and live scoring snapshots.

✦

Fun facts about Nurix Therapeutics, Inc.

Quirks, history, and lore behind NRIX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in San Francisco, California · focused on a cutting-edge area of cell biology.
2
The Numbers
A pre-revenue biotech with a market cap in the hundreds of millions — spending heavily on R&D while its pipeline advances through clinical trials.
3
The History
Founded around 2014, the company was built to exploit a relatively new understanding of how cells tag proteins for destruction — a process the body uses constantly but science had barely touched as a drug target.
4
The Secret
Its entire platform is built around E3 ubiquitin ligases — enzymes that slap a molecular 'delete me' label on proteins, letting the cell's own proteasome do the dirty work of elimination.
5
The Lore
The company has partnered with Gilead Sciences in a deal worth potentially over a billion dollars, targeting diseases where degrading a bad protein beats merely blocking it.
6
The Giveaway
Its very name telegraphs the mission: Nurturing the science of targeted protein degradation via the ubiquitin pathway — ticker NRIX, the 'ix' hinting at therapeutics built to delete disease at its source.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$9.0M

Net Income

Q2 2026

$-89.5M

Free Cash Flow

Q2 2026

$-98.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+54.0% YoY

$84.0MFY 2025

FY21 $29.8MFY23 $77.0MFY24 $54.5MFY25 $84.0M

Net Income

-36.6% YoY

$-264.5MFY 2025

FY21 $-117.2MFY23 $-143.9MFY24 $-193.6MFY25 $-264.5M

Operating Income

-34.1% YoY

$-285.7MFY 2025

FY21 $-117.9MFY23 $-155.1MFY24 $-213.0MFY25 $-285.7M

EPS (Diluted)

-5.9% YoY

$-3.05FY 2025

FY21 $-2.73FY23 $-2.65FY24 $-2.88FY25 $-3.05

Total Assets

+2.8% YoY

$688.1MFY 2025

FY21 $476.8MFY23 $355.6MFY24 $669.3MFY25 $688.1M

Op. Cash Flow

-44.5% YoY

$-249.5MFY 2025

FY21 $-84.4MFY23 $-81.4MFY24 $-172.6MFY25 $-249.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$84.0M +54.0%	$54.5M -29.1%	$77.0M +158.8%	$29.8M +66.9%	$17.8M	—
Net Income	$-264.5M -36.6%	$-193.6M -34.5%	$-143.9M -22.8%	$-117.2M -171.0%	$-43.2M	—
Operating Income	$-285.7M -34.1%	$-213.0M -37.4%	$-155.1M -31.5%	$-117.9M -81.4%	$-65.0M	—
EPS (Diluted)	$-3.05 -5.9%	$-2.88 -8.7%	$-2.65 +2.9%	$-2.73	—	—
Total Assets	$688.1M +2.8%	$669.3M +88.2%	$355.6M -25.4%	$476.8M +20.3%	$396.3M	—
Operating Cash Flow	$-249.5M -44.5%	$-172.6M -112.1%	$-81.4M +3.6%	$-84.4M -105356.3%	$-80.0K	—

Get alerted when NRIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Nurix Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NRIX

BlackRock, Inc.
$138.3M8,925,642 sh
Redmile Group, LLC
$119.9M7,732,808 sh
Vestal Point Capital, LP
$100.8M6,500,000 sh
Deep Track Capital, LP
$98.4M6,345,244 sh
FMR LLC
$85.9M5,541,271 sh
STATE STREET CORP
$79.7M5,141,195 sh
MORGAN STANLEY
$76.4M4,931,999 sh
BAKER BROS. ADVISORS LP
$72.2M4,658,556 sh
VANGUARD CAPITAL MANAGEMENT LLC
$68.6M4,427,112 sh
GENERAL ATLANTIC, L.P.
$63.6M4,101,865 sh

Fund	Value	Shares
BlackRock, Inc.	$138.3M	8,925,642
Redmile Group, LLC	$119.9M	7,732,808
Vestal Point Capital, LP	$100.8M	6,500,000
Deep Track Capital, LP	$98.4M	6,345,244
FMR LLC	$85.9M	5,541,271
STATE STREET CORP	$79.7M	5,141,195
MORGAN STANLEY	$76.4M	4,931,999
BAKER BROS. ADVISORS LP	$72.2M	4,658,556
VANGUARD CAPITAL MANAGEMENT LLC	$68.6M	4,427,112
GENERAL ATLANTIC, L.P.	$63.6M	4,101,865

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NRIX on your watchlist

Track score changes the day Nurix Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NRIX a good stock to buy?

13F Pro's AI-powered analysis of Nurix Therapeutics, Inc. (NRIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRIX are available on the NRIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NRIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nurix Therapeutics, Inc.'s investment landscape.